Literature DB >> 29528942

Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular Clones.

Agnes-Laurence Chenine1,2,3, Melanie Merbah1,2, Lindsay Wieczorek1,2, Sebastian Molnar1,2, Brendan Mann1,2, Jenica Lee1,2, Anne-Marie OʼSullivan1,2, Meera Bose1,2, Eric Sanders-Buell1,2, Gustavo H Kijak1,2,4, Carolina Herrera5, Robert McLinden1,2,6, Robert J OʼConnell7, Nelson L Michael1, Merlin L Robb1,2, Jerome H Kim1,8, Victoria R Polonis1, Sodsai Tovanabutra1,2.   

Abstract

BACKGROUND: HIV-1 CRF01_AE is dominant in Thailand where RV144 vaccine trial was conducted. To study immune correlates of protection in ongoing trials, CRF01_AE-derived reagents are essential. Here, we present a panel of 14 HIV-1 infectious molecular clones (IMCs) identified from different stages of infection and characterization of their neutralization sensitivity using 2 standard assays.
METHODS: One full-length IMC was constructed using a transmitted-founder virus to express Renilla luciferase (LucR) reporter gene and full-length envelopes (envs) of exogenous HIV-1. A panel of IMCs was generated, expressing envs of viruses from acute (Fiebig stages I/II and I-IV) and chronic (>Fiebig VI) infection. Neutralization assays were performed using TZM-bl or A3R5 cell lines, and sera or monoclonal antibodies (mAbs). Wilcoxon matched-paired test was used to assess neutralization differences between assays and reagents; correlation coefficients were evaluated by linear regression.
RESULTS: Neutralization potency observed was significantly higher in the A3R5 assay when testing mAbs and serum pools (P < 0.0001); the stage of infection from which env was derived did not associate with IMC neutralization sensitivity. Neutralization values from A3R5 and TZM-bl assays were strongly correlated when mAbs were tested (R = 0.7, P < 0.0001), but a weaker association was seen with serum pools (R = 0.17, P = 0.03).
CONCLUSIONS: This novel panel of CRF01_AE reporter IMC is useful for assessing vaccine-induced neutralizing antibodies in multiple assays, including those using primary cell targets. The significant differences in TZM-bl and A3R5 neutralization sensitivity, as well as the poor association when using polyclonal sera indicates the need for caution in choosing one specific platform.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29528942      PMCID: PMC5997515          DOI: 10.1097/QAI.0000000000001675

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  42 in total

1.  Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic.

Authors:  Zelda Euler; Evelien M Bunnik; Judith A Burger; Brigitte D M Boeser-Nunnink; Marlous L Grijsen; Jan M Prins; Hanneke Schuitemaker
Journal:  J Virol       Date:  2011-05-11       Impact factor: 5.103

2.  Construction and biological characterization of infectious molecular clones of HIV-1 subtypes B and E (CRF01_AE) generated by the polymerase chain reaction.

Authors:  M O Salminen; P K Ehrenberg; J R Mascola; D E Dayhoff; R Merling; B Blake; M Louder; S Hegerich; V R Polonis; D L Birx; M L Robb; F E McCutchan; N L Michael
Journal:  Virology       Date:  2000-12-05       Impact factor: 3.616

3.  Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration.

Authors:  Vidita Choudhry; Mei-Yun Zhang; Ilia Harris; Igor A Sidorov; Bang Vu; Antony S Dimitrov; Timothy Fouts; Dimiter S Dimitrov
Journal:  Biochem Biophys Res Commun       Date:  2006-08-04       Impact factor: 3.575

4.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

5.  Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.

Authors:  Marcella Sarzotti-Kelsoe; Robert T Bailer; Ellen Turk; Chen-li Lin; Miroslawa Bilska; Kelli M Greene; Hongmei Gao; Christopher A Todd; Daniel A Ozaki; Michael S Seaman; John R Mascola; David C Montefiori
Journal:  J Immunol Methods       Date:  2013-12-01       Impact factor: 2.303

6.  Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmission.

Authors:  Hong Zhang; Marzena Rola; John T West; Damien C Tully; Piotr Kubis; Jun He; Chipepo Kankasa; Charles Wood
Journal:  Virology       Date:  2010-01-25       Impact factor: 3.616

7.  International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials.

Authors:  Daniel A Ozaki; Hongmei Gao; Christopher A Todd; Kelli M Greene; David C Montefiori; Marcella Sarzotti-Kelsoe
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240

8.  Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.

Authors:  David C Montefiori; Chitraporn Karnasuta; Ying Huang; Hasan Ahmed; Peter Gilbert; Mark S de Souza; Robert McLinden; Sodsai Tovanabutra; Agnes Laurence-Chenine; Eric Sanders-Buell; M Anthony Moody; Mattia Bonsignori; Christina Ochsenbauer; John Kappes; Haili Tang; Kelli Greene; Hongmei Gao; Celia C LaBranche; Charla Andrews; Victoria R Polonis; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Steve G Self; Phillip W Berman; Donald Francis; Faruk Sinangil; Carter Lee; Jim Tartaglia; Merlin L Robb; Barton F Haynes; Nelson L Michael; Jerome H Kim
Journal:  J Infect Dis       Date:  2012-05-25       Impact factor: 5.226

9.  Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses.

Authors:  Susan Zolla-Pazner; Paul T Edlefsen; Morgane Rolland; Xiang-Peng Kong; Allan deCamp; Raphael Gottardo; Constance Williams; Sodsai Tovanabutra; Sandra Sharpe-Cohen; James I Mullins; Mark S deSouza; Nicos Karasavvas; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Punnee Pitisuttihum; Jaranit Kaewkungwal; Robert J O'Connell; Merlin L Robb; Nelson L Michael; Jerome H Kim; Peter Gilbert
Journal:  EBioMedicine       Date:  2014-11-01       Impact factor: 8.143

10.  Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection.

Authors:  Jesus F Salazar-Gonzalez; Maria G Salazar; Brandon F Keele; Gerald H Learn; Elena E Giorgi; Hui Li; Julie M Decker; Shuyi Wang; Joshua Baalwa; Matthias H Kraus; Nicholas F Parrish; Katharina S Shaw; M Brad Guffey; Katharine J Bar; Katie L Davis; Christina Ochsenbauer-Jambor; John C Kappes; Michael S Saag; Myron S Cohen; Joseph Mulenga; Cynthia A Derdeyn; Susan Allen; Eric Hunter; Martin Markowitz; Peter Hraber; Alan S Perelson; Tanmoy Bhattacharya; Barton F Haynes; Bette T Korber; Beatrice H Hahn; George M Shaw
Journal:  J Exp Med       Date:  2009-06-01       Impact factor: 14.307

View more
  3 in total

1.  Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.

Authors:  Karl Stefic; Mélanie Bouvin-Pley; Asma Essat; Clara Visdeloup; Alain Moreau; Cécile Goujard; Marie-Laure Chaix; Martine Braibant; Laurence Meyer; Francis Barin
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

2.  Detection of the HIV-1 Accessory Proteins Nef and Vpu by Flow Cytometry Represents a New Tool to Study Their Functional Interplay within a Single Infected CD4+ T Cell.

Authors:  Jérémie Prévost; Jonathan Richard; Romain Gasser; Halima Medjahed; Frank Kirchhoff; Beatrice H Hahn; John C Kappes; Christina Ochsenbauer; Ralf Duerr; Andrés Finzi
Journal:  J Virol       Date:  2022-01-26       Impact factor: 6.549

3.  The HIV-1 Env gp120 Inner Domain Shapes the Phe43 Cavity and the CD4 Binding Site.

Authors:  Jérémie Prévost; William D Tolbert; Halima Medjahed; Rebekah T Sherburn; Navid Madani; Daria Zoubchenok; Gabrielle Gendron-Lepage; Althea E Gaffney; Melissa C Grenier; Sharon Kirk; Natasha Vergara; Changze Han; Brendan T Mann; Agnès L Chénine; Adel Ahmed; Irwin Chaiken; Frank Kirchhoff; Beatrice H Hahn; Hillel Haim; Cameron F Abrams; Amos B Smith; Joseph Sodroski; Marzena Pazgier; Andrés Finzi
Journal:  mBio       Date:  2020-05-26       Impact factor: 7.867

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.